Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) PT at $25.56

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has earned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $25.56.

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald cut their price objective on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Morgan Stanley downgraded ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $28.00 to $20.00 in a report on Wednesday, August 7th. Royal Bank of Canada decreased their price target on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, August 8th. Finally, StockNews.com raised ACADIA Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 13th.

ACADIA Pharmaceuticals Stock Up 1.4 %

Shares of ACAD stock opened at $15.69 on Tuesday. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -1,569.00, a PEG ratio of 0.55 and a beta of 0.40. The stock has a fifty day moving average of $16.57 and a 200 day moving average of $16.58. ACADIA Pharmaceuticals has a 52 week low of $14.55 and a 52 week high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.02. The firm had revenue of $241.96 million for the quarter, compared to the consensus estimate of $235.95 million. ACADIA Pharmaceuticals had a return on equity of 6.89% and a net margin of 3.43%. The company’s quarterly revenue was up 46.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.01 earnings per share. Equities research analysts anticipate that ACADIA Pharmaceuticals will post 0.52 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Stephen Davis sold 31,747 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total value of $485,094.16. Following the transaction, the chief executive officer now directly owns 186,555 shares in the company, valued at approximately $2,850,560.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other ACADIA Pharmaceuticals news, CEO Stephen Davis sold 31,747 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $485,094.16. Following the completion of the transaction, the chief executive officer now directly owns 186,555 shares in the company, valued at $2,850,560.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Brendan Teehan sold 9,534 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $145,679.52. Following the completion of the transaction, the chief operating officer now directly owns 52,177 shares of the company’s stock, valued at approximately $797,264.56. The disclosure for this sale can be found here. Insiders have sold 51,014 shares of company stock worth $779,494 in the last ninety days. 28.30% of the stock is currently owned by corporate insiders.

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ACAD. Fisher Asset Management LLC bought a new position in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $4,479,000. Perceptive Advisors LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth about $3,162,000. UBS Group AG increased its holdings in shares of ACADIA Pharmaceuticals by 112.4% during the 4th quarter. UBS Group AG now owns 307,359 shares of the biopharmaceutical company’s stock valued at $9,623,000 after acquiring an additional 162,663 shares during the last quarter. M&G Plc bought a new position in shares of ACADIA Pharmaceuticals in the 1st quarter valued at approximately $5,622,000. Finally, Capital Fund Management S.A. lifted its holdings in ACADIA Pharmaceuticals by 38.8% in the 4th quarter. Capital Fund Management S.A. now owns 243,812 shares of the biopharmaceutical company’s stock worth $7,634,000 after purchasing an additional 68,120 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.